149 related articles for article (PubMed ID: 9858850)
1. Intermittent Complete Androgen Blockade in Metastatic Prostate Cancer.
Rambeaud J
Eur Urol; 1998 Dec; 35 Suppl S1():32-36. PubMed ID: 9858850
[TBL] [Abstract][Full Text] [Related]
2. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
3. Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up.
Goldenberg SL; Gleave ME; Taylor D; Bruchovsky N
Mol Urol; 1999; 3(3):287-292. PubMed ID: 10851335
[TBL] [Abstract][Full Text] [Related]
4. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
Pether M; Goldenberg SL; Bhagirath K; Gleave M
Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
[TBL] [Abstract][Full Text] [Related]
5. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
6. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
[TBL] [Abstract][Full Text] [Related]
7. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study.
Higano CS; Ellis W; Russell K; Lange PH
Urology; 1996 Nov; 48(5):800-4. PubMed ID: 8911533
[TBL] [Abstract][Full Text] [Related]
8. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
[TBL] [Abstract][Full Text] [Related]
9. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.
Goldenberg SL; Bruchovsky N; Gleave ME; Sullivan LD; Akakura K
Urology; 1995 May; 45(5):839-44; discussion 844-5. PubMed ID: 7538246
[TBL] [Abstract][Full Text] [Related]
10. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
11. Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients.
Oliver RT; Farrugia D; Ansell W; Williams G; Chinegwundoh F
Prostate Cancer Prostatic Dis; 2000 Dec; 3(4):286-289. PubMed ID: 12497080
[TBL] [Abstract][Full Text] [Related]
12. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.
Bruchovsky N; Klotz LH; Sadar M; Crook JM; Hoffart D; Godwin L; Warkentin M; Gleave ME; Goldenberg SL
Mol Urol; 2000; 4(3):191-9;discussion 201. PubMed ID: 11062374
[TBL] [Abstract][Full Text] [Related]
13. [Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].
Gleave M; Santo N; Rennie PS; Goldenberg SL; Bruchovsky N; Sullivan LD
Prog Urol; 1996 Jun; 6(3):375-85. PubMed ID: 8763692
[TBL] [Abstract][Full Text] [Related]
14. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
Bruchovsky N; Klotz L; Crook J; Malone S; Ludgate C; Morris WJ; Gleave ME; Goldenberg SL
Cancer; 2006 Jul; 107(2):389-95. PubMed ID: 16783817
[TBL] [Abstract][Full Text] [Related]
15. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
16. Innovative approaches to the hormonal treatment of advanced prostate cancer.
Trachtenberg J
Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
[TBL] [Abstract][Full Text] [Related]
17. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome.
Malone S; Perry G; Eapen L; Segal R; Gallant V; Dahrouge S; Crook J; Spaans JN
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):699-706. PubMed ID: 17379438
[TBL] [Abstract][Full Text] [Related]
18. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
[TBL] [Abstract][Full Text] [Related]
19. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
20. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]